Cardiosense is building a physiological waveform AI platform to develop predictive biomarkers to detect and manage cardiac disease. The Company has developed a suite of novel digital tools, multi-sensor devices, and analysis algorithms to detect early signs of cardiovascular disease, inform personalized therapy, and improve patient outcomes.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 12/08/22 | $15,100,000 | Series A |
Broadview Ventures Hatteras Venture Partners Laerdal Million Lives Fund OSF Ventures Portal Innovations UnityPoint Health Ventures | undisclosed |
